Skip to main content

Market Overview

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Share:
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

Arvinas, Inc. (NASDAQ:ARVN) and Pfizer Inc. (NYSE:PFE) released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer.

The results of the trial, released Monday, included estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer patients whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy.

These are the first pivotal data for vepdegestrant.

The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant.

Also Read: Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients

The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population.

The trial did not reach statistical significance in improvement in PFS in the intent-to-treat (ITT) population.

Overall survival was not mature at the time of the analysis, with less than a quarter of the required number of events having occurred.

The trial will continue to assess overall survival as a key secondary endpoint.

In the trial, vepdegestrant was generally well tolerated.

Detailed results from VERITAC-2 will be submitted for presentation at a medical meeting later this year.

In February 2024, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for vepdegestrant for monotherapy for adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.

Price Action: ARVN stock is down 52.4% at $8.35 at the last check Tuesday.

Read Next:

Image: Shutterstock

 

Related Articles (PFE + ARVN)

View Comments and Join the Discussion!

Posted-In: breast cancerBiotech Large Cap News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com